LA
TXG icon

LM Advisors’s 10x Genomics TXG Stock Holding History

LM Advisors’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-23
Closed -$1.28K – 668
2023
Q4 		$1.28K Buy
+23
New +$1K ﹤0.01% 687

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

LM Advisors's TXG Position: Q1 2024 in Review

LM Advisors sold out of 10x Genomics (TXG) in Q1 2024, closing a stake of 23 shares — an estimated $1.28K sold.

LM Advisors first reported a position in TXG in Q4 2023 and held it in 1 quarter. The position peaked at $1.28K in Q4 2023. 290 funds tracked by Wall St. Rank hold TXG as of Q1 2024.

  • LM Advisors reported no remaining 10x Genomics position as of Q1 2024 after selling out during the quarter.
  • LM Advisors sold 23 10x Genomics shares in Q1 2024, an estimated $1.28K.
  • LM Advisors first reported a position in 10x Genomics in Q4 2023 and held it in 1 quarter.
  • LM Advisors's 10x Genomics position peaked at $1.28K in Q4 2023.
  • 290 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2024.

Based on LM Advisors's 13F filing for Q1 2024, filed 15 May 2024.